Clevidipine

Summary

Clevidipine (CHEMBL1237132) is an approved small molecule (ATC C08CA16); indicated across 6 conditions including cardiovascular disorder and hypertensive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C08CA16
• Indications: 6 conditions
• Clinical trials: 25
• Chemistry: 456.3 Da · C21H23Cl2NO6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1237132
Name	Clevidipine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	153994
ATC	C08CA16
Molecular formula	C21H23Cl2NO6
Molecular weight	456.3
InChIKey	KPBZROQVTHLCDU-UHFFFAOYSA-N

SMILES: CCCC(=O)OCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C

IUPAC name: 5-O-(butanoyloxymethyl) 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate

Also known as: Clevidepine, Clevidepine butyrate, Clevidipine, Clevidipino, Cleviprex, H-324/38, H324/38, CLEVIDIPINE, Celvidipine, SID170466066, CLEVIDIPINE BUTYRATE, cleviprex

Patent coverage: 1,122 distinct patent families (3,762 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,316 (88%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Voltage-dependent L-type calcium channel subunit alpha-1C, Bile salt export pump.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
O35505	8.15	IC50	7.1	nM	CHEMBL_ACT_15373208
O35505	7.1	IC50	78.8	nM	CHEMBL_ACT_15373209

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319
hypertensive disorder	3	MONDO:0005044	EFO:0000537
malignant hypertension	3	MONDO:0006846	EFO:1001031
stroke disorder	3	MONDO:0005098	EFO:0000712
scoliosis	2	MONDO:0005392	EFO:0004273
vascular disorder	0	MONDO:0005385	EFO:0004264

Clinical trials

Total trials: 25.

Phase distribution

Phase	Trials
PHASE3	9
PHASE4	8
PHASE2	3
Not specified	3
PHASE2/PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06063772	PHASE4	NOT_YET_RECRUITING	Effect of Treatment of Pre-induction Hypertension on Hemodynamic Stability During Induction of General Anesthesia
NCT00952081	PHASE4	COMPLETED	A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients
NCT01042574	PHASE4	WITHDRAWN	The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy
NCT01121458	PHASE4	COMPLETED	Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed
NCT01526876	PHASE4	WITHDRAWN	The Effect of Clevidipine on Intracranial Pressure and Cerebral Perfusion Pressure (CCP) in Brain Injured Patients
NCT01910532	PHASE4	WITHDRAWN	The Evaluation of Clevidipine in Patients Requiring ICP Monitoring and IV Antihypertensive Therapy
NCT01938547	PHASE4	TERMINATED	Assessment of Efficacy, Safety and Dosing of Clevidipine in Pediatric Participants Undergoing Surgery (PIONEER)
NCT03300479	PHASE4	WITHDRAWN	Clevidipine (Cleviprex®) Compared With Urapidil (Ebrantil®)
NCT00093249	PHASE3	COMPLETED	Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-1)
NCT00093262	PHASE3	COMPLETED	Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-2)
NCT00093886	PHASE3	COMPLETED	Clevidipine in the Perioperative Treatment of Hypertension (ECLIPSE-NTG)
NCT00093912	PHASE3	COMPLETED	Clevidipine in the Perioperative Treatment of Hypertension (ECLISPE-SNP)
NCT00093925	PHASE3	COMPLETED	Clevidipine in the Postoperative Treatment of Hypertension (ECLIPSE-NIC)
NCT00369837	PHASE3	COMPLETED	Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)
NCT00666328	PHASE3	COMPLETED	Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)
NCT00803634	PHASE3	COMPLETED	Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)
NCT01645111	PHASE2/PHASE3	COMPLETED	An Open-label Trial of Clevidipine for Controlled Hypotension During Spinal Fusion
NCT05175547	PHASE3	COMPLETED	Clevidipine Infusion for Blood Pressure Management After Successful Revascularization in Acute Ischemic Stroke
NCT00799604	PHASE2	COMPLETED	Clevidipine Bolus Administration in the Treatment of Hypertensive Patients Undergoing Cardiac Surgery (SPRINT)
NCT01369147	PHASE2	TERMINATED	The Energy Dose Study
NCT02011321	PHASE2	WITHDRAWN	Clevidipine for Vasospasm After Subarachnoid Hemorrhage (SAH)
NCT03719001	EARLY_PHASE1	COMPLETED	Effect of Changing Physiological Conditions on Myogenic Oscillations: Pilot Study
NCT06402968	Not specified	RECRUITING	Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
NCT01480531	Not specified	WITHDRAWN	Pre and or Post Operative Blood Pressure Control With Clevidipine (Cleviprexm Medicines Company) in Aortic Aneurysm / Dissection
NCT05168059	Not specified	COMPLETED	Clevidipine in Neurocritical Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).